Recent Updates — SXTP
60 Degrees Pharmaceuticals entered into inducement letter agreements with holders of existing warrants to exercise them at a reduced price of $0.90 per share, generating approximately $526,043 in gross proceeds. In exchange, the company issued new unregistered warrants for 1,168,984 shares, representing 200% of the exercised shares. The transaction is expected to close around November 9, 2026, subject to stockholder approval and customary conditions. Proceeds will support working capital and general corporate purposes. This biotechnology company focuses on developing pharmaceutical products.
60 Degrees Pharmaceuticals announced that all five completed patients in its expanded access study for relapsing babesiosis reported much or very much improved clinical outcomes and tested negative for Babesia on conventional PCR tests. Four of the five patients (80%) were also nonreactive on a highly sensitive post-treatment nucleic acid amplification test (NAT). Two additional patients remain on treatment, bringing total enrollment to seven. The company plans to pursue accelerated approval if the efficacy section of its registration dossier is based primarily on data from immunosuppressed patients with relapsing babesiosis. 60 Degrees Pharmaceuticals develops and commercializes new medicines for the treatment and prevention of vector-borne disease.
60 Degrees Pharmaceuticals plans to unblind its randomized clinical study of tafenoquine in patients hospitalized with severe babesiosis and report primary and secondary endpoint results in January 2027. The Data Safety Monitoring Board recommended concluding enrollment at the current 30 subjects rather than adding three more, avoiding a potential delay until fall 2027. No safety signals were identified during the interim analysis. The company also intends to request a pre-sNDA meeting with the FDA in January 2027 to discuss regulatory pathways for treating babesiosis. 60 Degrees Pharmaceuticals develops and commercializes new medicines for vector-borne disease.
On September 12, 2026, 60 Degrees Pharmaceuticals submitted a Statement of Interest to the FDA requesting a Commissioner’s National Priority Voucher for tafenoquine (ARAKODA) as a treatment for babesiosis. The company cites compelling efficacy signals from published case reports and an expanded access study where all three evaluable patients were cured. A randomized controlled trial is complete, with Data Safety Monitoring Board analysis scheduled for October 1, 2026. If successful, the company targets supplemental New Drug Application submission in March–April 2027, aiming for approval before the 2027 tick season. This biopharmaceutical company develops and commercializes pharmaceutical products.
60 Degrees Pharmaceuticals, Inc. filed a Form 8-K on September 8, 2026, to furnish an updated investor presentation dated for the same day under Item 7.01 of Regulation FD. The presentation outlines the company's strategy to expand its marketed antimalarial product ARAKODA (tafenoquine) into treatments for tick-borne diseases, specifically babesiosis. It details a commercial base generating $208k in Q2 2026 net product revenue and highlights a July 31, 2026 private placement that raised approximately $1.0M at $1.74 per share. The company reports pro forma cash and equivalents of roughly $1.0M as of late July, providing an operating runway into early October 2026. The filing also notes a Series A non-voting convertible preferred stock balance with a 6% cumulative dividend following a Knight conversion. This biopharmaceutical company focuses on targeted therapies for vector-borne diseases.